CTNM FY 2023 Earnings — Contineum Therapeutics, Inc. Class A Common Stock Revenue & Financial Results | Market Cap Arena

CTNMContineum Therapeutics, Inc. Class A Common Stock

$504M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M

Gross Profit

$50M100.0% margin

Operating Income

-$16M-32.2% margin

Net Income

$23M45.4% margin

EPS (Diluted)

$0.90

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

$19M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$130M

Total Liabilities

$198M

Stockholders' Equity

-$68M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$0	—
Gross Profit	$50M	-$329,000	+15297.6%
Operating Income	-$16M	-$23M	+29.2%
Net Income	$23M	-$24M	+193.7%